Erasca Revamps With Two In-Licensings, $160m Follow-On Offering

 
• By Joseph Haas
  
pancreatic cancer
Erasca is pursuing targeted therapies for solid tumors like pancreatic cancer • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business